Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wayne C. Schairer is active.

Publication


Featured researches published by Wayne C. Schairer.


Bioorganic & Medicinal Chemistry Letters | 1998

Design and synthesis of novel conformationally restricted HIV protease inhibitors

Francesco Salituro; Christopher T. Baker; John J. Court; David D. Deininger; Eunice E. Kim; Biquin Li; Perry M. Novak; Bhisetti Govinda Rao; S. Pazhanisamy; Margaret D. Porter; Wayne C. Schairer; Roger D. Tung

A set of HIV protease inhibitors represented by compound 2 has previously been described. Structural and conformational analysis of this compound suggested that conformational restriction of the P1/P2 portion of the molecule could lead to a novel set of potent protease inhibitors. Thus, probe compounds 3-7 were designed, synthesized, and found to be potent inhibitors of HIV protease.


Bioorganic & Medicinal Chemistry Letters | 1993

Achiral internucleoside linkages: CH2-CH2-NH and nH-CH2-CH2 linkages

Thomas J. Caulfield; C.V.C. Prasad; Catherine Prouty; Ashis K. Saha; M.P. Sardaro; Wayne C. Schairer; Anne M. Yawman; Donald A. Upson; Lawrence I. Kruse

The synthesis of CH2-CH2-NH and NH-CH2-CH2 internucleoside linkages are described. Antisense oligonucleosides containing these dimer modifications hybridized to the sense sequence. Furthermore incorporation of these backbone modifications enhanced the nuclease resistance of the antisense strand.


Bioorganic & Medicinal Chemistry Letters | 1998

Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors

Christopher T. Baker; Francesco Salituro; John J. Court; David D. Deininger; Eunice E. Kim; Biquin Li; Perry M. Novak; Bhisetti Govinda Rao; S. Pazhanisamy; Wayne C. Schairer; Roger D. Tung

A combination of structure-based design and both solution, and solid-phase synthesis were utilized to derive a potent (nM) series of HIV-1 protease inhibitors bearing a structurally novel backbone. Detailed structural analysis of several inhibitors prepared in this series has suggested that rigidification of the P1/P2 region of this class of molecules may result in compounds with improved potency.


Bioorganic & Medicinal Chemistry Letters | 1995

Achiral internucleoside linkages 3: CH2NHCH2 linkage

C.V.C. Prasad; Thomas J. Caulfield; Catherine Prouty; Ashis K. Saha; Wayne C. Schairer; Anne M. Yawman; Donald A. Upson; Lawrence I. Kruse

Abstract A stereoselective method for the synthesis of 3′-α-or 3′-β-carbon substituted pyrimidine nucleosides was developed. The synthesis of the CH 2 NHCH 2 linkage is described. The linkage offers enhanced resistance to 3′-exonuclease.


Archive | 2000

Inhibitors of aspartyl protease

Michael R. Hale; Roger D. Tung; Stephen Price; Robin David Wilkes; Wayne C. Schairer; Ashley Nicholas Jarvis; Andrew Spaltenstein; Eric S. Furfine; Vicente Samano; Istvan Kaldor; John F. Miller; Michael Stephen Brieger; Ronald G. Sherrill


Bioorganic & Medicinal Chemistry Letters | 2004

Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants

Robert B. Perni; Luc J. Farmer; Kevin M. Cottrell; John J. Court; Lawrence F. Courtney; David D. Deininger; Cynthia A. Gates; Scott L. Harbeson; Joseph L. Kim; Chao Lin; Kai Lin; Yu-Ping Luong; John Maxwell; Mark A. Murcko; Janos Pitlik; B. Govinda Rao; Wayne C. Schairer; Roger D. Tung; John H. Van Drie; Keith P. Wilson; John A. Thomson


Bioorganic & Medicinal Chemistry Letters | 2003

Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.

Robert B. Perni; Shawn D. Britt; John C. Court; Lawrence F. Courtney; David D. Deininger; Luc J. Farmer; Cynthia A. Gates; Scott L. Harbeson; Joseph L. Kim; James A. Landro; Rhonda B. Levin; Yu-Ping Luong; Ethan T. O'Malley; Janos Pitlik; B.Govinda Rao; Wayne C. Schairer; John A. Thomson; Roger D. Tung; John H. Van Drie; Yunyi Wei


Bioorganic & Medicinal Chemistry Letters | 2007

Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.

Robert B. Perni; Gurudatt Chandorkar; Kevin M. Cottrell; Cynthia A. Gates; Chao Lin; Kai Lin; Yu-Ping Luong; John Maxwell; Mark A. Murcko; Janos Pitlik; Govinda Rao; Wayne C. Schairer; John H. Van Drie; Yunyi Wei


Letters in Drug Design & Discovery | 2005

Inhibitors of Hepatitis C Virus NS3.4A Protease: P2 Proline Variants

Luc J. Farmer; Shawn D. Britt; Kevin M. Cottrell; John J. Court; Lawrence F. Courtney; David D. Deininger; Cynthia A. Gates; Scott L. Harbeson; Kai Lin; Chao Lin; Yu P. Luong; John Maxwell; Janos Pitlik; Bhisetti Govinda Rao; Wayne C. Schairer; John A. Thomson; Roger D. Tung; John H. Van Drie; Yunyi Wei; Robert B. Perni


Archive | 2008

Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents

Michael R. Hale; Roger D. Tung; Stephen Price; Robin David Wilkes; Wayne C. Schairer; Ashley Nicholas Jarvis; Andrew Spaltenstein; Eric S. Furfine; Vicente Samano; Istvan Kaldor; John Miller; Michael Stephen Brieger

Collaboration


Dive into the Wayne C. Schairer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John J. Court

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar

Robert B. Perni

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John A. Thomson

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge